Marshall Wace, LLP Sangamo Therapeutics, Inc Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 576,219 shares of SGMO stock, worth $501,310. This represents 0.0% of its overall portfolio holdings.

Number of Shares

576,219

Previous 368,743 56.27%

Holding current value

$501,310

Previous $247,000 16.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.36 - $0.65 $74,691 - $134,859	207,476 Added 56.27%	576,219 $207,000
Q1 2024 May 15, 2024	BUY	$0.42 - $1.38 $154,872 - $508,865	368,743 New	368,743 $247,000
Q4 2020 Feb 16, 2021	SELL	$9.23 - $18.18 $102,702 - $202,288	-11,127 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.38 - $12.48 $104,371 - $138,864	11,127 New	11,127 $105,000
Q2 2020 Aug 13, 2020	SELL	$6.21 - $11.83 $8.46 Million - $16.1 Million	-1,363,039 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.05 - $8.85 $5.22 Million - $9.15 Million	1,033,713 Added 313.89%	1,363,039 $8.68 Million
Q4 2019 Feb 14, 2020	BUY	$8.03 - $11.7 $2.38 Million - $3.47 Million	296,968 Added 917.76%	329,326 $2.76 Million
Q3 2019 Nov 14, 2019	BUY	$9.05 - $12.22 $292,839 - $395,414	32,358 New	32,358 $293,000
Q1 2019 May 14, 2019	SELL	$7.72 - $12.81 $5.5 Million - $9.13 Million	-712,657 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$9.51 - $16.6 $6.65 Million - $11.6 Million	699,089 Added 5152.48%	712,657 $8.18 Million
Q3 2018 Nov 14, 2018	BUY	$13.05 - $19.05 $177,062 - $258,470	13,568 New	13,568 $230,000

Others Institutions Holding SGMO

# of Institutions

133

Shares Held

86.3M

Call Options Held

35.9K

Put Options Held

156K

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $136M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Sangamo Therapeutics, Inc Transaction History